Method for diagnosing and assessing risk of pancreatitis using genetic variants
The present application discloses methods for predicting the risk of developing, or the presence of, recurrent acute pancreatitis and/or chronic pancreatitis, in a subject, by identifying the presence of an rs12688220 T allele, an rs7057398 T allele, and/or an rs10273639 C allele in a sample from the subject. The present application also discloses methods for treating or preventing pancreatitis in a human subject in need thereof.
1. A method for treating pancreatitis in a human subject in need thereof comprising:
(a) testing a sample from the subject for the presence of a rs12688220 T allele, a rs7057398 T allele, and a rs10273639 C allele,
wherein the presence of an allele is detected by an assay selected from the group consisting of polymerase chain reaction, quantitative polymerase chain reaction, nucleic acid sequencing, and nucleic acid microarray analysis; and
(b) where the rs12688220 T allele is present in the sample,
administering a treatment for pancreatitis to the subject selected from the group consisting of cholecystectomy, biliary sphincterotomy, administration of an antibiotic, administration of carbapenem, administration of a therapeutic enzyme, surgery, distal pancreatectomy, celiac nerve block, percutaneous drainage, and combinations thereof.
2. The method of claim 1 , further comprising, prior to treatment administration, a diagnostic procedure selected from the group consisting of a biochemical assay for isoamylase, lipase, trypsin, elastase, and/or secretin level in a sample from the subject, quantitative measurement of fecal fat, measurement of plasma cholecystokinin (CCK), assay for pancreatic exocrine function, radiological testing, transabdominal ultrasound, CT scanning, magnetic resonance cholangiopancreatography (MRCP), endoscopic diagnosis assay, and combination thereof.
3. A method for treating pancreatitis in a human subject in need thereof comprising:
(a) testing a sample from the subject for the presence of a rs12688220 T allele, a rs7057398 T allele, and a rs10273639 C allele,
wherein the presence of an allele is detected by an assay selected from the group consisting of polymerase chain reaction, quantitative polymerase chain reaction, nucleic acid sequencing, and nucleic acid microarray analysis; and
(b) where the rs7057398 T allele is present in the sample,
administering a treatment for pancreatitis to the subject selected from the group consisting of cholecystectomy, biliary sphincterotomy, administration of an antibiotic, administration of carbapenem, administration of a therapeutic enzyme, surgery, distal pancreatectomy, celiac nerve block, percutaneous drainage, and combinations thereof.
4. The method of claim 3 , further comprising, prior to treatment administration, a diagnostic procedure selected from the group consisting of a biochemical assay for isoamylase, lipase, trypsin, elastase, and/or secretin level in a sample from the subject, quantitative measurement of fecal fat, measurement of plasma cholecystokinin (CCK), assay for pancreatic exocrine function, radiological testing, transabdominal ultrasound, CT scanning, magnetic resonance cholangiopancreatography (MRCP), endoscopic diagnosis assay, and combination thereof.
5. A method for treating pancreatitis in a human subject in need thereof comprising:
(a) testing a sample from the subject for the presence of a rs12688220 T allele, a rs7057398 T allele, and a rs10273639 C allele,
wherein the presence of an allele is detected by an assay selected from the group consisting of polymerase chain reaction, quantitative polymerase chain reaction, nucleic acid sequencing, and nucleic acid microarray analysis; and
(b) where the rs10273639 C allele is present in the sample,
administering a treatment for pancreatitis to the subject selected from the group consisting of cholecystectomy, biliary sphincterotomy, administration of an antibiotic, administration of carbapenem, administration of a therapeutic enzyme, surgery, distal pancreatectomy, celiac nerve block, percutaneous drainage, and combinations thereof.
6. The method of claim 5 , further comprising, prior to treatment administration, a diagnostic procedure selected from the group consisting of a biochemical assay for isoamylase, lipase, trypsin, elastase, and/or secretin level in a sample from the subject, quantitative measurement of fecal fat, measurement of plasma cholecystokinin (CCK), assay for pancreatic exocrine function, radiological testing, transabdominal ultrasound, CT scanning, magnetic resonance cholangiopancreatography (MRCP), endoscopic diagnosis assay, and combination thereof.
7. The method of claim 1 , comprising determining the presence of nucleic acid comprising SEQ ID NO:2 in the sample.